Diabetes Research and Clinical Practice
Volume 72, Issue 3 , Pages 238-243 , June 2006

A case of slowly progressive type 1 diabetes with unstable glycemic control caused by unusual insulin antibody and successfully treated with steroid therapy

  • Akiko Matsuyoshi

      Affiliations

    • Department of Metabolic Medicine, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Japan
    • ,
  • Seiya Shimoda

      Affiliations

    • Department of Metabolic Medicine, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Japan
    • ,
  • Kaku Tsuruzoe

      Affiliations

    • Department of Metabolic Medicine, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Japan
    • ,
  • Kayo Taketa

      Affiliations

    • Department of Metabolic Medicine, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Japan
    • ,
  • Takeshi Chirioka

      Affiliations

    • Comprehensive Clinical Education, Training and Development Center, Kumamoto University, Japan
    • ,
  • Fumi Sakamoto

      Affiliations

    • Comprehensive Clinical Education, Training and Development Center, Kumamoto University, Japan
    • ,
  • Michiharu Sakakida

      Affiliations

    • Department of Metabolic Medicine, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Japan
    • ,
  • Nobuhiro Miyamura

      Affiliations

    • Department of Metabolic Medicine, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Japan
    • ,
  • Eiichi Araki

      Affiliations

    • Department of Metabolic Medicine, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Japan
    • Corresponding Author InformationCorresponding author at: Department of Metabolic Medicine, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, 1-1-1, Honjo, Kumamoto 860-8556, Japan. Tel.: +81 96 373 5169; fax: +81 96 366 8397.

Received 7 June 2005 ,Revised 5 August 2005 ,Accepted 18 October 2005.

References 

  1. Van Haeften TW. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care. 1989;12:641–648
  2. Lahtela JT, Knip M, Paul R, Antonen J, Salmi J. Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. Diabetes Care. 1997;20:71–73
  3. Asai M, Kodera T, Ishizeki K, Uebori S, Kashiwaya T, Itoh H, et al. Insulin lispro reduces insulin antibodies in a patient with type 2 diabetes with immunological insulin resistance. Diabetes Res. Clin. Pract. 2003;61:89–92
  4. Dahl-Jorgensen K, Torjesen P, Hanssen KF, Sandvik L, Aagenaes O. Increase in insulin antibodies during continuous subcutaneous insulin infusion and multiple-injection therapy in contrast to conventional treatment. Diabetes. 1987;36:1–5
  5. Scatchard G. The attraction of proteins for small molecules and ions. Ann. NY Acad. Sci. 1949;51:660–672
  6. Uehara M, Kishikawa H, Isami S, Kisanuki K, Ohkubo Y, Miyamura N, et al. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans. Diabetologia. 1994;37:300–307
  7. Eguchi Y. Scatchard analysis of insulin autoantibodies in the insulin autoimmune syndrome. Tokyo Joshi Ikadaigaku Zasshi. 1989;59:1296–1305(in Japanese)
  8. Berson SA, Yalow RS, Bauman A, Rothschild MA, Newerly K. Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. J. Clin. Invest. 1956;35:170–190
  9. Kurtz AB, Gray RS, Markanday S, Nabarro JD. Circulating IgG antibody to protamine in patients treated with protamine-insulins. Diabetologia. 1983;25:322–324
  10. Vaitukaitis J, Robbins JB, Nieschlag E, Ross GT. A method for producing specific antisera with small doses of immunogen. J. Clin. Endocrinol. Metab. 1971;33:988–991
  11. Reeves WG, Barr D, Douglas CA, Gelsthorpe K, Hanning I, Skene A, et al. Factors governing the human immune response to injected insulin. Diabetologia. 1984;26:266–271
  12. Hirata Y, Uchigata Y. Insulin autoimmune syndrome in Japan. Diabetes Res. Clin. Pract. 1994;24(Suppl):S153–S157
  13. Hirata Y, Ishizu H, Motomura M, Abe M, Hara Y, Wakasugi H, et al. Insulin autoimmunity in a case of spontaneous hypoglycemia. J. Jpn. Diabetes. 1970;13:312–320(in Japanese)
  14. Uchigata Y, Tokunaga K, Nepom G, Bannai M, Kuwata S, Dozio N, et al. Differential immunogenetic determinants of polyclonal insulin autoimmune syndrome (Hirata's disease) and monoclonal insulin autoimmune syndrome. Diabetes. 1995;44(10):1227–1232
  15. Matsushita S, Takahashi K, Motoki M, Komoriya K, Ikagawa S, Nishimura Y. Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and DRB1*0406 complexes: implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome. J. Exp. Med. 1994;180(3):873–883
  16. Kobayashi T, Tamemoto K, Nakanishi K, Kato N, Okubo M, Kajio H, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care. 1993;16:780–788
  17. Micic D, Brkic S, Kendereski A, Popovic V, Zoric S, Nikolic JA, et al. Immunological resistance to human biosynthetic insulin—effects of immunosuppression and plasmapheresis. Diabetes Res. Clin. Pract. 1993;19:83–89
  18. Miyamura N, Murata Y, Taketa K, Ichihara Y, Matsumura T, Tokunaga H, et al. A case of insulin autoimmune syndrome with HLA DRB1*0404: impact on the hypothesis for the molecular pathogenesis involving the DRB1 molecules. Diabetes Med. 2006;23:104–105

PII: S0168-8227(05)00424-9

doi: 10.1016/j.diabres.2005.10.018

Diabetes Research and Clinical Practice
Volume 72, Issue 3 , Pages 238-243 , June 2006

Article Tools

* Image Usage & Resolution